Jump to content

Tetrahydrocannabinol

Frae Wikipedia, the free beuk o knawledge
Tetrahydrocannabinol
Clinical data
Tred namesMarinol
Leecence data
Pregnancy
category
  • US: C (Risk nae ruled oot)
Dependence
liability
8–10% (Relatively low risk of tolerance)[1]
Routes o
admeenistration
Orally, local/topical, transdermal, sublingual, inhaled
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability10–35% (inhalation), 6–20% (oral)[3]
Protein bindin97–99%[3][4][5]
MetabolismMaistly hepatic by CYP2C[3]
Biological hauf-life1.6–59 h,[3] 25–36 h (orally administered dronabinol)
Excretion65–80% (feces), 20–35% (urine) as acid metabolites[3]
Identifiers
SynonymsDronabinol
CAS Nummer
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
ChEBI
ChEMBL
ECHA InfoCard100.153.676
Chemical and physical data
FormulaC21H30O2
Molar mass314.469 g/mol
3D model (Jmol)
Specific rotation-152° (ethanol)
Bylin pynt157 °C (315 °F) [7]
Solubility in watter0.0028,[6] (23 °C) mg/mL (20 °C)
 NYesY (whit is this?)  (verify)

Tetrahydrocannabinol (THC), or mair precisely its main isomer (−)-trans9-tetrahydrocannabinol ((6aR,10aR)-delta-9-tetrahydrocannabinol), is the principal psychoactive constituent (or cannabinoid) o cannabis.

References

[eedit | eedit soorce]
  1. Marlowe, Douglas B. (December 2010). "The Facts On Marijuana". NADCP. Based upon several nationwide epidemiological studies, marijuana’s dependence liability has been reliably determined to be 8 to 10 percent. Cite journal requires |journal= (help)
  2. "Archived copy" (PDF). Archived frae the original (PDF) on 13 Mey 2014. Retrieved 9 November 2015.CS1 maint: archived copy as title (link)
  3. a b c d e Grotenhermen, F (2003). "Pharmacokinetics and pharmacodynamics of cannabinoids". Clin Pharmacokinet. 42 (4): 327–60. doi:10.2165/00003088-200342040-00003. PMID 12648025. Unknown parameter |subscription= ignored (help)
  4. The Royal Pharmaceutical Society of Great Britain (30 November 2006). "Cannabis". In Sean C. Sweetman (ed.). Martindale: The Complete Drug Reference: Single User (35th ed.). Pharmaceutical Press. ISBN 978-0-85369-703-9.[page needit]
  5. "Tetrahydrocannabinol – Compound Summary". National Center for Biotechnology Information. PubChem. Retrieved 12 Januar 2014. Dronabinol has a large apparent volume of distribution, approximately 10 L/kg, because of its lipid solubility. The plasma protein binding of dronabinol and its metabolites is approximately 97%.
  6. Garrett ER, Hunt CA (Julie 1974). "Physicochemical properties, solubility, and protein binding of Δ9-tetrahydrocannabinol". J. Pharm. Sci. 63 (7): 1056–64. doi:10.1002/jps.2600630705. PMID 4853640.
  7. McPartland JM, Russo EB (2001). "Cannabis and cannabis extracts: greater than the sum of their parts?" (PDF). Journal of Cannabis Therapeutics. 1 (3/4): 103–132. doi:10.1300/J175v01n03_08. Archived frae the original (PDF) on 22 Juin 2017. Retrieved 9 November 2015.